FIRST TR EXCHANGE-TRADED FD - NY ARCA BIOTECH (FBT)

Historical Portfolio Holders from Q1 2014 to Q3 2024

All holders as of September 30, 2024
Q3 2024
Type / Class
Equity / NY ARCA BIOTECH
Shares, excl. options Q3 2024
3.29M
Holdings value Q3 2024
$566M
Value change Q3 2024
-$20.1M
Grand Portfolio weight change Q3 2024
0%
Number of holders
244
Number of buys Q3 2024
79
Number of sells Q3 2024
-115
Average buys Q3 2024 %
+0%
Average sells Q3 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 3.29M $566M -$20.1M $171.93 244
2024 Q2 3.46M $533M -$22M $153.99 245
2024 Q1 3.58M $550M -$66.2M $153.77 237
2023 Q4 4.01M $634M -$30.1M $158.06 251
2023 Q3 4.18M $612M -$62.8M $146.35 237
2023 Q2 4.61M $706M -$19.9M $153.14 245
2023 Q1 4.69M $727M -$18M $155.03 239
2022 Q4 4.87M $750M +$55.8M $154.13 236
2022 Q3 4.48M $592M +$22M $131.98 209
2022 Q2 4.32M $586M -$18.1M $135.56 215
2022 Q1 4.44M $662M -$83M $149.14 209
2021 Q4 4.95M $801M -$47.5M $161.96 237
2021 Q3 5.18M $860M -$14.2M $166.06 229
2021 Q2 5.22M $901M -$80.6M $172.62 226
2021 Q1 5.73M $919M -$21.4M $160.50 231
2020 Q4 5.81M $976M -$78.2M $167.99 230
2020 Q3 6.09M $959M -$31.8M $157.26 208
2020 Q2 6.22M $1.04B +$191M $167.77 220
2020 Q1 5.15M $676M -$47M $131.12 191
2019 Q4 5.48M $816M -$74.7M $148.72 205
2019 Q3 5.99M $743M -$883M $123.76 183
2019 Q2 12.6M $1.77B +$35.8M $140.84 216
2019 Q1 12.4M $1.86B +$129M $150.85 224
2018 Q4 11.7M $1.45B -$404M $124.20 191
2018 Q3 14.2M $2.25B +$1.43B $158.49 187
2018 Q2 5.13M $719M +$65.8M $140.01 153
2018 Q1 4.67M $620M +$89.6M $132.90 150
2017 Q4 3.98M $496M +$44.8M $124.57 125
2017 Q3 3.61M $447M +$13.8M $123.93 115
2017 Q2 3.49M $398M +$56M $114.04 111
2017 Q1 3.02M $317M -$4.72M $105.30 112
2016 Q4 3.1M $282M +$13.6M $90.87 108
2016 Q3 2.91M $289M -$409K $99.71 109
2016 Q2 3.08M $275M -$39.7M $89.43 106
2016 Q1 3.36M $294M -$1.89B $87.56 104
2015 Q4 21.8M $2.46B +$164M $113.02 127
2015 Q3 20.1M $2.04B +$162M $101.32 127
2015 Q2 18.5M $2.29B +$283M $124.02 123
2015 Q1 16.1M $1.91B +$445M $118.23 118
2014 Q4 12.3M $1.26B +$246M $102.02 108
2014 Q3 9.63M $884M +$85.6M $91.78 95
2014 Q2 8.69M $716M +$32.2M $82.33 91
2014 Q1 8.32M $638M +$51.7M $76.69 82